UPDATE ON DRUGS
|Class||Name/Company||Approval Dates and Comments|
|Zoster Vaccine Live|
|The US FDA approved this new vaccine in May 2006 for the|
prevention of herpes zoster (shingles) in individuals 60 years of age
and older. It is given as a single dose by injection.
|The US FDA approved this product in May 2006 for the|
treatment of inflammatory lesions (papules and pustules) of
rosacea in adult patients.
|The US FDA approved this dermal filler in June 2005 for the|
treatment of facial wrinkles and folds. Juvéderm® should only
be administered by a trained and qualified health care provider.
|The US FDA granted orphan drug designation for this|
immunosuppressive agent in June 2006 for the treatment of
Hydroxamic Acid (SAHA) Zolinza®
|The US FDA accepted a New Drug Application for this|
investigational histone deacetylase inhibitor in June 2006 for the
treatment of advanced cutaneous T-cell lymphoma. This NDA
has been granted priority review.
|The US FDA approved this vaccine in June 2006 for the|
prevention of cervical cancer and vulvar and vaginal precancers
caused by HPV types 16 and 18 and to prevent low-grade and
precancerous lesions and genital warts caused by HPV types 6,
11, 16 and 18.
|The European Medicines Agency approved this tumor necrosis|
factor (TNF)-blocking agent in June 2006 for the treatment of
severe ankylosing spondylitis.
|Twelve-week data were recently published* from a multinational, randomized, double-blind,|
placebo-controlled, parallel-group clinical study designed to evaluate the safety and efficacy of
efalizumab (Raptiva®) 1.0mg/kg once weekly when compared with placebo. Investigators found
that efalizumab produced significant clinical improvements and was generally well tolerated
among patients with moderate-to-severe plaque psoriasis.
*Dubertret L, Sterry W, Bos JD, et al. Br J Dermatol 155(1):170-81 (2006 Jul).
|According to a recent study of Welsh school children published in the Archives of Disease in|
Childhood*, four out of five head lice are resistant to common treatments containing pyrethroids
(permethrin and phenothrin). Whether this pattern is reflected elsewhere will depend on how head
lice treatments are used. However, they suggest that where resistance develops, a newer silicone based
lotion might be a suitable alternative.
*Thomas DR, McCarroll L, Roberts R, et al. Arch Dis Child [Epub ahead of print] (2006 June 14).